Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;14(1):e70517.
doi: 10.1002/cam4.70517.

Turn TRAIL Into Better Anticancer Therapeutic Through TRAIL Fusion Proteins

Affiliations
Review

Turn TRAIL Into Better Anticancer Therapeutic Through TRAIL Fusion Proteins

Yan Wang et al. Cancer Med. 2025 Jan.

Abstract

Background: TNF-related apoptosis-inducing ligand (TRAIL) belongs to the tumor necrosis factor superfamily. TRAIL selectively induces apoptosis in tumor cells while sparing normal cells, which makes it an attractive candidate for cancer therapy. Recombinant soluble TRAIL and agonistic antibodies against TRAIL receptors have demonstrated safety and tolerability in clinical trials. However, they have failed to exhibit expected clinical efficacy. Consequently, extensive research has focused on optimizing TRAIL-based therapies, with one of the most common approaches being the construction of TRAIL fusion proteins.

Methods: An extensive literature search was conducted to identify studies published over the past three decades related to TRAIL fusion proteins. These various TRAIL fusion strategies were categorized based on their effects achieved.

Results: The main fusion strategies for TRAIL include: 1. Construction of stable TRAIL trimers; 2. Enhancing the polymerization capacity of soluble TRAIL; 3. Increasing the accumulation of TRAIL at tumor sites by fusing with antibody fragments or peptides; 4. Decorating immune cells with TRAIL; 5. Prolonging the half-life of TRAIL in vivo; 6. Sensitizing cancer cells to overcome resistance to TRAIL treatment.

Conclusion: This work focuses on the progress in recombinant TRAIL fusion proteins and aims to provide more rational and effective fusion strategies to enhance the efficacy of recombinant soluble TRAIL, facilitating its translation from bench to bedside as an effective anti-cancer therapeutic.

Keywords: TRAIL; apoptosis; cancer; fusion protein; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
The apoptotic and non‐apoptotic pathways of TRAIL.

Similar articles

Cited by

References

    1. Dianat‐Moghadam H., Heidarifard M., Mahari A., et al., “TRAIL in Oncology: From Recombinant TRAIL to Nano‐ and Self‐Targeted TRAIL‐Based Therapies,” Pharmacological Research 155 (2020): 104716. - PubMed
    1. Thapa B., Kc R., and Uludag H., “TRAIL Therapy and Prospective Developments for Cancer Treatment,” Journal of Controlled Release 326 (2020): 335–349. - PubMed
    1. Takeda K., Hayakawa Y., Smyth M. J., et al., “Involvement of Tumor Necrosis Factor‐Related Apoptosis‐Inducing Ligand in Surveillance of Tumor Metastasis by Liver Natural Killer Cells,” Nature Medicine 7 (2001): 94–100. - PubMed
    1. Bodmer J. L., Meier P., Tschopp J., and Schneider P., “Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL,” Journal of Biological Chemistry 275 (2000): 20632–20637. - PubMed
    1. Wajant H., “Molecular Mode of Action of TRAIL Receptor Agonists‐Common Principles and Their Translational Exploitation,” Cancers (Basel) 11 (2019): 954. - PMC - PubMed

MeSH terms

Substances